Our PDX experiments demonstrate the effectiveness of Cetuximab in suppressing tumor growth in CHD6-high CRC and also point out that in addition to WT Ras/Raf status, expression level of CHD6 is critical for determining the treatment efficacy of Cetuximab. This evidence concerns the gene CHD6 and neoplasm.